FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011034128> ?p ?o ?g. }

• W3011034128 endingPage "319" @default.
• W3011034128 startingPage "312" @default.
• W3011034128 abstract "Abstract Background Currently, no specific treatment exists for heart failure with preserved ejection fraction (HFpEF). Left ventricular (LV) relaxation during diastole is a highly energy-demanding process, while energy homeostasis is known to be compromised in HFpEF. We hypothesise that trimetazidine – a fatty acid β‑oxidation inhibitor – improves LV diastolic function in HFpEF, by altering myocardial substrate use and improving the myocardial energy status. Objectives To assess whether trimetazidine improves LV diastolic function by improving myocardial energy metabolism in HFpEF. Methods The DoPING-HFpEF trial is a randomised, double-blind, placebo-controlled cross-over intervention trial comparing the efficacy of trimetazidine and placebo in 25 patients with stable HFpEF. The main inclusion criteria are: New York Heart Association functional class II to IV, LV ejection fraction ≥50%, and evidence of LV diastolic dysfunction. Patients are treated with one 20-mg trimetazidine tablet or placebo thrice daily (twice daily in the case of moderate renal dysfunction) for two periods of 3 months separated by a 2-week washout period. The primary endpoint is the change in pulmonary capillary wedge pressure during different intensities of exercise measured by right heart catheterisation. Our key secondary endpoint is the myocardial phosphocreatine (PCr)/ATP ratio measured by phosphorus-31 magnetic resonance spectroscopy and its relation to the primary endpoint. Exploratory endpoints are 6‑min walk distance, N -terminal pro-brain natriuretic peptide levels, and quality of life. Conclusion The DoPING-HFpEF is a phase-II trial that evaluates the effect of trimetazidine, a metabolic modulator, on diastolic function and myocardial energy status in HFpEF. [EU Clinical Trial Register: 2018-002170-52; NTR registration: NL7830]" @default.
• W3011034128 created "2020-03-23" @default.
• W3011034128 creator A5013104694 @default.
• W3011034128 creator A5019619566 @default.
• W3011034128 creator A5024148692 @default.
• W3011034128 creator A5028653037 @default.
• W3011034128 creator A5029194436 @default.
• W3011034128 creator A5070504139 @default.
• W3011034128 creator A5088103668 @default.
• W3011034128 date "2020-03-11" @default.
• W3011034128 modified "2023-10-10" @default.
• W3011034128 title "TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study" @default.
• W3011034128 cites W164205712 @default.
• W3011034128 cites W1973860737 @default.
• W3011034128 cites W2005511622 @default.
• W3011034128 cites W2019999805 @default.
• W3011034128 cites W2057547167 @default.
• W3011034128 cites W2062229924 @default.
• W3011034128 cites W2070250452 @default.
• W3011034128 cites W2086619682 @default.
• W3011034128 cites W2137784332 @default.
• W3011034128 cites W2143725549 @default.
• W3011034128 cites W2156677237 @default.
• W3011034128 cites W2166504467 @default.
• W3011034128 cites W2167018359 @default.
• W3011034128 cites W2170375510 @default.
• W3011034128 cites W2268647522 @default.
• W3011034128 cites W2280632351 @default.
• W3011034128 cites W2311933573 @default.
• W3011034128 cites W2427094903 @default.
• W3011034128 cites W2552276063 @default.
• W3011034128 cites W2565443325 @default.
• W3011034128 cites W2602132542 @default.
• W3011034128 cites W2604584410 @default.
• W3011034128 cites W2619820809 @default.
• W3011034128 cites W2761341410 @default.
• W3011034128 cites W2769425716 @default.
• W3011034128 cites W2769453207 @default.
• W3011034128 cites W2810857007 @default.
• W3011034128 cites W2889002990 @default.
• W3011034128 cites W2921482995 @default.
• W3011034128 cites W4253503843 @default.
• W3011034128 doi "https://doi.org/10.1007/s12471-020-01407-z" @default.
• W3011034128 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7270414" @default.
• W3011034128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32162204" @default.
• W3011034128 hasPublicationYear "2020" @default.
• W3011034128 type Work @default.
• W3011034128 sameAs 3011034128 @default.
• W3011034128 citedByCount "8" @default.
• W3011034128 countsByYear W30110341282020 @default.
• W3011034128 countsByYear W30110341282021 @default.
• W3011034128 countsByYear W30110341282022 @default.
• W3011034128 countsByYear W30110341282023 @default.
• W3011034128 crossrefType "journal-article" @default.
• W3011034128 hasAuthorship W3011034128A5013104694 @default.
• W3011034128 hasAuthorship W3011034128A5019619566 @default.
• W3011034128 hasAuthorship W3011034128A5024148692 @default.
• W3011034128 hasAuthorship W3011034128A5028653037 @default.
• W3011034128 hasAuthorship W3011034128A5029194436 @default.
• W3011034128 hasAuthorship W3011034128A5070504139 @default.
• W3011034128 hasAuthorship W3011034128A5088103668 @default.
• W3011034128 hasBestOaLocation W30110341281 @default.
• W3011034128 hasConcept C126322002 @default.
• W3011034128 hasConcept C142724271 @default.
• W3011034128 hasConcept C164705383 @default.
• W3011034128 hasConcept C203092338 @default.
• W3011034128 hasConcept C204787440 @default.
• W3011034128 hasConcept C27081682 @default.
• W3011034128 hasConcept C2777099384 @default.
• W3011034128 hasConcept C2777927741 @default.
• W3011034128 hasConcept C2778198053 @default.
• W3011034128 hasConcept C535046627 @default.
• W3011034128 hasConcept C71924100 @default.
• W3011034128 hasConcept C78085059 @default.
• W3011034128 hasConceptScore W3011034128C126322002 @default.
• W3011034128 hasConceptScore W3011034128C142724271 @default.
• W3011034128 hasConceptScore W3011034128C164705383 @default.
• W3011034128 hasConceptScore W3011034128C203092338 @default.
• W3011034128 hasConceptScore W3011034128C204787440 @default.
• W3011034128 hasConceptScore W3011034128C27081682 @default.
• W3011034128 hasConceptScore W3011034128C2777099384 @default.
• W3011034128 hasConceptScore W3011034128C2777927741 @default.
• W3011034128 hasConceptScore W3011034128C2778198053 @default.
• W3011034128 hasConceptScore W3011034128C535046627 @default.
• W3011034128 hasConceptScore W3011034128C71924100 @default.
• W3011034128 hasConceptScore W3011034128C78085059 @default.
• W3011034128 hasIssue "6" @default.
• W3011034128 hasLocation W30110341281 @default.
• W3011034128 hasLocation W30110341282 @default.
• W3011034128 hasLocation W30110341283 @default.
• W3011034128 hasLocation W30110341284 @default.
• W3011034128 hasOpenAccess W3011034128 @default.
• W3011034128 hasPrimaryLocation W30110341281 @default.
• W3011034128 hasRelatedWork W2061321770 @default.
• W3011034128 hasRelatedWork W2159564278 @default.
• W3011034128 hasRelatedWork W2789205885 @default.
• W3011034128 hasRelatedWork W2965474825 @default.
• W3011034128 hasRelatedWork W3013207865 @default.

• next